Posts

Posted on

Sky Harbour Group Corporation Announces its 2023 Q1 Financial Results, Update on Leasing Activities and the Closing of its Acquisition of RapidBuilt

Sky Harbour Group Corporation Announces its 2023 Q1 Financial Results, Update on Leasing Activities and the Closing of its Acquisition of RapidBuilt

WEST HARRISON, N.Y.–(BUSINESS WIRE)–
Sky Harbour Group Corporation (NYSE American: SKYH, SKYH WS) (“SHG” or the “Company”), an aviation infrastructure company building the first nationwide network of Home-Basing Solutions for business aircraft, announced the release of its 2023 1st quarter Financial Results in Form 10-Q. Please see the following link to access the filing:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001823587/000143774923014229/ysac20230331_10q.htm

Highlights of the results and other recent events are:

  • Q1 2023 Revenues increased 179% as compared to Q1 2022 and 82% compared to Q4 2022

  • S,G&A expenses decreased 23% compared to Q1 2022

  • Strong liquidity and capital resources as of March 31, 2023, including cash, restricted cash, and US Treasury investments of over $165 million

  • Closed the Project Modification and recapitalization of wholly owned Sky Harbour Capital, with a significant increase in the already robust projected debt service coverage of the Series 2021 Bonds1
  • New executed hangar tenant lease rents reach record mid-$40s per square foot

  • Houston, Nashville and Miami facilities are 94%, 64% and 67% leased, respectively, as of May 12, 2023. Full occupancy projected to be reached by end of Q3 2023.

On May 12, 2023, the Company exercised its option to acquire a controlling stake in Overflow LP, owner of Rapidbuilt Inc. (“RapidBuilt”), a Texas based manufacturer of pre-engineered metal buildings (PEMB). The Company previously executed a strategic supply agreement with RapidBuilt in July 2022 to guarantee production capacity and achieve optimum manufacturing margin for its hangar construction projects. With the closing of this acquisition, the Company believes that the vertical integration will enable it to deliver hangar buildings to each of the Company’s development sites in shorter timeframes, reducing the overall construction cost and duration of each of its projects. The Company paid nominal consideration for its initial 51% equity stake and agreed to assume its senior loan obligations of approximately $10 million. This acquisition is intended to be accretive to SKYH through immediate projected construction and operational savings. The 8-K filing related to this closing may be found on the link below:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001823587/000143774923014241/ysac20230511_8k.htm

Tal Keinan, Chairman and Chief Executive Officer, commented on the Q1 results and other recent events: “After operating its pilot campus in Houston for more than a year, Sky Harbour quickly grew to conducting full flight operations on three campuses, Nashville having opened in November 2022 and Miami in February 2023. As leasing nears completion, tenant feedback has been outstanding. Sky Harbour has taken a meaningful step forward in establishing its Home Basing Solution as the solution of choice for the country’s top aircraft owners.”

“The company’s attention is now increasingly focused on expanding Sky Harbour’s national footprint, continuing to refine Sky Harbour’s already unmatched service offering, and maximizing the economies of scale afforded by the Sky Harbour model.”

“As part of this effort, we are happy to welcome the RapidBuilt team into the Sky Harbour family. Vertical integration will produce considerable development cost advantages. More importantly, RapidBuilt brings the best engineering talent we have ever encountered in the Aviation PEMB and hangar-door spaces into the Sky Harbour prototyping process, yielding a constantly improving hangar, with outstanding quality consistency and a more efficient construction cycle.”

Sky Harbour campuses are open and operating at Houston’s Sugar Land Regional Airport (“SGR”), Nashville International Airport (“BNA”) and Miami Opa-Locka Executive Airport (“OPF”). Sky Harbour is developing new campuses at Denver Centennial Airport (“APA”) and Phoenix Deer Valley Airport (“DVT”), both of which are in construction, and Dallas Addison Airport (“ADS”), which is in permitting.

About Sky Harbour Group Corporation

Sky Harbour Group Corporation is an aviation infrastructure company developing the first nationwide network of Home-Basing Solutions for business aircraft. The company develops, leases and manages general aviation hangars across the United States. Sky Harbour’s Home-Basing Solution aims to provide private and corporate customers with the best physical infrastructure in business aviation, coupled with dedicated service tailored to based aircraft, offering the shortest time to wheels-up in business aviation. To learn more, visit www.skyharbour.group.

Forward Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements about the financial condition, results of operations, earnings outlook and prospects of SHG may include statements for the period following the consummation of the business combination. When used in this press release, the words “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements are based on the current expectations of the management of SHG as applicable and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those discussed and identified in the public filings made or to be made with the SEC by SHG, including the filings described above, regarding the following: expectations regarding SHG’s strategies and future financial performance, including its future business plans, expansion plans or objectives, prospective performance and opportunities and competitors, revenues, products and services, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures, and SHG’s ability to invest in growth initiatives; SHG’s ability to scale and build the hangars currently under development or planned in a timely and cost-effective manner; the implementation, market acceptance and success of SHG’s business model and growth strategy; the success or profitability of SHG’s hangar facilities; SHG’s future capital requirements and sources and uses of cash; SHG’s ability to obtain funding for its operations and future growth; developments and projections relating to SHG’s competitors and industry; the ability to recognize the anticipated benefits of the business combination; geopolitical risk and changes in applicable laws or regulations; the possibility that SHG may be adversely affected by other economic, business, and/or competitive factors; operational risk; risk that the COVID-19 pandemic, and local, state, and federal responses to addressing the pandemic may have an adverse effect on SHG’s business operations, as well as SHG’s financial condition and results of operations. Should one or more of these risks or uncertainties materialize or should any of the assumptions made by the management of SHG prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. SHG undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

1 Please see press release dated March 28, 2023 and related SEC filing.

Investor Relations:

[email protected]

Attn: Francisco X. Gonzalez, CFO

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Air Transport Aerospace Manufacturing Transportation Other Construction & Property Travel

MEDIA:

Logo
Logo
Posted on

FOX News Books to Release “Unbroken Bonds of Battle” by Retired Staff Sergeant Johnny Joey Jones on June 27th

FOX News Books to Release “Unbroken Bonds of Battle” by Retired Staff Sergeant Johnny Joey Jones on June 27th

“Unbroken Bonds of Battle: A Modern Warriors Book of Heroism, Patriotism and Friendship” Marks the Seventh Title for FOX News Books

NEW YORK–(BUSINESS WIRE)–
FOX News Books, FOX News Media’s publishing imprint, will release its seventh title on Tuesday, June 27th, “Unbroken Bonds of Battle,” by FOX News Channel (FNC) contributor, FOX Nation host and combat veteran Johnny Joey Jones. The book follows the Modern Warriors franchise debut title “Modern Warriors: Real Stories from Real Heroes” authored by FOX & Friends Weekend co-host and veteranPete Hegseth, which was a New York Times bestseller.

In commenting on the announcement, Jones remarked, “For years people have asked me to write a book about ‘my story.’ However, I’ve always known all along that the most important part of my story is the amazing collection of people and warriors who’ve become a part of my life. Each of them with inspiring and heroic stories of their own. It’s fitting that my first book is a telling of their stories, how they’ve affected my life and how their experience in serving this country shows the need for bonds on and beyond the battlefield. Unbroken Bonds is a book for, by and about patriotic Americans and what it truly means to be your brothers’ keeper.”

“Unbroken Bonds of Battle” marks the second installment of the growing Modern Warriors franchise, which spotlights those who have dedicated their lives to protecting the freedoms and the people of the United States of America. Staff Sergeant Jones served eight years in the Marine Corps with tours in Iraq and Afghanistan before an IED ended his career as a bomb technician, forever changing his life. Through the support of his brothers and sisters in arms, he began the arduous recovery and has since dedicated himself to paying it forward, working on behalf and with veterans for more than a decade. Featuring unfiltered and authentic conversations from across all branches of the military, Jones honors the true American heroes that not only defend this great nation, but protect their fellow warriors. With powerful lessons woven throughout these personal oral histories, along with a scrapbook of candid photos and an exploration of life, loss and even hunting, “Unbroken Bonds of Battle” will serve as a patriotic tribute to the tightknit community bonds built upon of faith, family and service.

Since the installment of FOX News Books, the publishing imprint has sold nearly 2 million copies, with each title placing on numerous national bestseller lists. The imprint launched in November 2020 with Hegseth’s “Modern Warriors: Real Stories from Real Heroes,” followed by Shannon Bream’s “The Women of the Bible Speak” (March 2021), “All American Christmas” by Rachel Campos-Duffy and Sean Duffy (November 2021), “The Mothers and Daughters of the Bible Speak” (March 2022), “Faith Still Move Mountains” by Harris Faulkner (October 2022) and most recently, “The Love Stories of the Bible Speak” (March 2023). Notably, every single FOX News Books title has made the New York Times bestsellers list, with Bream’s highly successful biblical “Speak” series, selling more than 1 million copies since launching in March 2021.

A FOX News Media contributor since 2019, Jones provides military and political analysis across all platforms including FOX News Channel, FOX Business Network (FBN), FOX News Audio and FOX Nation. He frequently serves as a co-host for FNC’s weekend programming, including The Big Saturday and The Big Sunday Show, as well as a substitute hosts across daytime and primetime programming. On FOX Nation, Jones has hosted several programs, including FOX Nation Outdoors, USA Ink, and Alive Day, a documentary dedicated to the harrowing day of his tragic accident and celebration of the life he was given after the explosion.

FOX News Media operates the FOX News Channel (FNC), FOX Business Network (FBN), FOX News Digital, FOX News Audio, FOX News Books, the direct-to-consumer streaming services FOX Nation and FOX News International and the free ad-supported television service FOX Weather. Currently the number one network in all of cable, FNC has also been the most watched television news channel for more than 21 consecutive years, while FBN is the top business channel on cable. Owned by Fox Corporation, FOX News Media reaches nearly 200 million people each month.

FOX News Media Contact:

Alexandra Coscia: 212.301.3272

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Women Publishing Men Communications General Entertainment Consumer Books Entertainment

MEDIA:

Logo
Logo
Posted on

Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process

To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings

Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations 
and Fulfill APD Customer Orders During Process

BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX) (“Athenex” or the “Company”), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company’s assets across its primary businesses: Athenex Pharmaceutical Division (“APD”), Orascovery, and Cell Therapy.

To best facilitate this process, Athenex and certain of its subsidiaries filed voluntary proceedings under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas. This will enable the Company to divest its assets and wind down the Athenex platform in an orderly fashion, while seeking to maximize value for its stakeholders. The Company anticipates concluding the expedited sales process by July 1, 2023, with the Chapter 11 cases continuing thereafter to resolve claims.

Athenex has also reached an agreement with its secured lenders, subject to court approval, for the consensual use of cash collateral, which will enable the Company to, among other things, satisfy certain obligations to its vendors for authorized goods received and services rendered after the filing. Athenex Pharma Solutions (“APS”), which includes the Company’s manufacturing facility in Clarence, New York, is expected to continue its operations for at least the next 90 days, to provide commercial supply of tirbanibulin ointment. In addition, APD is continuing to operate in the ordinary course and fill customer orders with the ample inventory it has on hand.

Dr. Johnson Lau, Chief Executive Officer of Athenex, on behalf of the management team and the Athenex Board of Directors, said, “Throughout our history, we have sought to become a leader in bringing innovative cancer treatments to the market and improving patient health outcomes. Our team was successful in bringing tirbanibulin, through regulatory approvals, to the U.S. market and a number of EU countries, as well as Taiwan. Unfortunately, our oral paclitaxel product candidate received a complete response letter from the U.S. Food and Drug Administration, and this significant regulatory setback, coupled with challenging biotech markets and the difficult economic environment, put tremendous pressure on our ability to continue to fund our businesses.

“Over the past two years, we made considerable progress in refocusing our business around our promising NKT cell therapy platform, monetizing non-core assets to improve our balance sheet and extending our cash runway, paying down $108 million of debt, and undertaking a comprehensive review of strategic alternatives to create value for our stakeholders. While we explored every viable avenue to avoid this outcome, an orderly sales process represents the best path forward at this time.

“Our goal remains to identify purchasers who will continue development of the important drug candidates for which we have established a good foundation, and to bring them to market on behalf of medical practitioners and, most importantly, for patients. We are incredibly thankful to our team for their dedication to Athenex and will look to support our colleagues through this transition period.”

Additional information regarding Athenex’s Chapter 11 filing is available at https://dm.epiq11.com/athenex; by calling the Company’s claims agent, Epiq, at 888-601-3094 (toll-free) or +1 503-433-8501 (international); or by sending an email to [email protected].

Pachulski Stang Ziehl & Jones LLP is acting as Athenex’s legal counsel. MERU is serving as its financial advisor and Cassel Salpeter & Co., LLC as its investment banker.

About Athenex, Inc.

Founded in 2003, Athenex, Inc. is a clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next-generation cell therapy products for the treatment of cancer. The Company’s mission is to become a leader in bringing innovative cancer treatments to the market and to improve patient health outcomes. In pursuit of this mission, Athenex leverages years of experience in research and development, clinical trials, regulatory standards, and manufacturing. The Company is focused on its innovative Cell Therapy platform, based on natural killer T (“NKT”) cells. For more information, please visit www.athenex.com.

Forward-Looking Statements

Except for historical information, information in this press release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words such as “anticipate,” “could,” “expect,” “may,” “seek,” “will,” and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Actual results might differ materially from those explicit or implicit in the forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions including: risks inherent in the bankruptcy process, including the Company’s ability to obtain approval from the Bankruptcy Court for motions or other requests made throughout the course of the Chapter 11 proceedings; the Company’s liquidity and financial position; the effects of the Chapter 11 proceedings on the Company’s operations; the Company’s ability to continue to operate its business during the pendency of the Chapter 11 proceedings, and the availability of operating capital during the Chapter 11 proceedings; the Company’s ability to maintain relationships with partners, suppliers, customers, employees, regulatory authorities and other third parties; the length of time that the Company will operate under Chapter 11 protection; objections to the Company’s restructuring or liquidation process, third-party motions, or other pleadings filed that could protract the Chapter 11 proceedings; and Bankruptcy Court rulings in the Chapter 11 proceedings and the outcome of the Chapter 11 proceedings, in general. You should not rely upon forward-looking statements as predictions of future events. The Company undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in its expectations, except as required by law.

Investor Contacts

[email protected]

716.427.2952

Media Contacts

Daniel Yunger / Wendi Kopsick
Kekst CNC
[email protected] 



Posted on

Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023

COPENHAGEN, Denmark, May 13, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will present clinical and research outcomes in hypoparathyroidism and growth hormone deficiency, and host informational booth and events, at ECE 2023, the European Congress of Endocrinology being held May 13-16 in Istanbul, Turkey. ECE gathers international professionals to share the latest science and clinical practice across the fields of endocrinology and metabolism.

“Ascendis is committed to creating novel therapies with best-in-class safety, efficacy, tolerability, and convenience,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “We are pleased to showcase our advancing Endocrinology portfolio, the meaningful differences we are making for patients, and our work to bring new treatment options to the European Union.”

Following are the five Ascendis Pharma posters at ECE 2023:

ABSTRACT

   PRESENTING AUTHOR
Hypoparathyroidism    
  • TransCon PTH Improves Health-Related Quality of Life and Reduces Work Limitations in Adults with Hypoparathyroidism: Patient-Reported Outcomes in the Phase 3 PaTHway Trial
  Christopher Sibley, M.D.

Poster
Display Date 14 May
Program code: P432
Session #969
  • Healthcare Resource Utilization Associated with Post-Surgical and Non-Surgical Chronic Hypoparathyroidism in England: A Linked Clinical Practice Research Datalink, Hospital Episode Statistics, and Office for National Statistics Retrospective Analysis
  Christopher Sibley, M.D.

Program code: P301
Display date:
15 May Poster
Session #986
Growth Hormone Deficiency    
  • Patient-Centric Design of the Lonapegsomatropin Auto-Injector for Pediatric Growth Hormone Deficiency
  Nils Berg Madsen, Ph.D.

e-Poster
Program code: EP745
Session #999
  • Design of the foresiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly Lonapegsomatropin to Placebo and Daily Somatropin in Adults with Growth Hormone Deficiency (GHD)
  Aleksandra Gilis-Januszewska, M.D., Ph.D.

Poster
Program code: P432
Display date: 15 May
Session #897
  • A Low Incidence of Transient Anti-Drug Antibodies Is Observed Upon Long-Term Exposure to Lonapegsomatropin in Children with Growth Hormone Deficiency
  Per Holse Mygind, Ph.D.

Poster
Program code: P702
Display date: 16 May
Session #975
     

About Ascendis Pharma A/S

Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated, global biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Germany (Heidelberg, Berlin and Munich) and the United States (Palo Alto and Redwood City, California, and Princeton, New Jersey). Visit ascendispharma.com to learn more.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated, global biopharma company, and (ii) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in its development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on its business from the worldwide COVID-19 pandemic and ongoing conflicts such as that in the region surrounding Ukraine and Russia. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 16, 2023 and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, and TransCon are trademarks owned by the Ascendis Pharma group. © May 2023 Ascendis Pharma A/S.

     

Investor Contacts:
 		 
Media Contact:
Tim Lee   Melinda Baker
Ascendis Pharma   Ascendis Pharma
+1 (650) 374-6343   +1 (650) 709-8875

[email protected]
 		 
[email protected]

[email protected]
 		   
     
Patti Bank    
ICR Westwicke    
+1 (415) 513-1284    

[email protected]
 		   

 



Posted on

Coty Introduces Orveda Serum and Infiniment Coty Paris Fragrance as the Company Charts a New Course at Gala Event in Cannes

Coty Introduces Orveda Serum and Infiniment Coty Paris Fragrance as the Company Charts a New Course at Gala Event in Cannes

  • Coty unveils new OmniPotent Concentrate serum under ultra-premium skincare brand Orveda

  • Coty outlines plans for Infiniment Coty Paris, the future of niche fragrance

  • Together, these brands chart a new course for Coty fusing art, science, and sustainability

CANNES, France–(BUSINESS WIRE)–
Today, Coty Inc. (NYSE: COTY), one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, skin and body care, announces the launch of an innovative new serum by ultra-premium skincare line Orveda and Infiniment Coty Paris, the Company’s most ambitious fragrance project to date.

On the eve of the Cannes Film Festival, at a gala launch event held at the renowned Villa Botanica attended by celebrities and beauty editors from around the world, Coty unveiled “Coty Protopia,” its vision for empowering bold and creative expressions of beauty. Rooted in Coty’s deep industry heritage, Coty Protopia represents a new approach to power beauty through cutting-edge innovation and science, underpinned by the Company’s commitment to sustainability and new art.

“At Coty, we firmly believe that no one can control or dictate what is, or is not, beautiful. The future of beauty we strive to create is one anchored in a deep respect for, and commitment to, infinite expressions of individual beauty and experiences,” said Sue Y. Nabi, Chief Executive Officer of Coty. “This ethos is embodied in our latest innovations, Orveda’s new Omnipotent Concentrate serum, which I believe is perhaps the most potent serum of all time. Infiniment Coty Paris, our most ambitious fragrance project to date, aims to usher in a new era for fragrances and perfumery, representing to fragrance what Orveda is to skincare.”

In her opening speech at the launch event, Sue Y. Nabi also celebrated Coty’s 30-year partnership with DKMS, one of the most significant non-profit organizations in the fight against blood cancer, as well as the largest stem cell donor center worldwide. Katharina Harf, DKMS global Chairman, spoke of the organization’s mission and ethos before sharing a moving film highlighting some of its critical projects and lifesaving initiatives, thanks in part to the support of Coty.

As part of the event to launch Orveda’s Omnipotent Concentrate serum and Infiniment Coty Paris, over 100 VIP guests were able to sample a selection of Orveda’s products and hear from the scientific and creative teams behind these two new innovations. Singer-songwriter LP also gave a special performance before guests enjoyed dinners that were specially curated by multi- Michelin starred chef Dominique Crenn.

Orveda

Founded in 2014, Orveda is a pioneer renowned for accelerating the microbiome and prebiotics science in skincare, with all products being vegan, sustainably-minded, and genderless.

“As part of our continued quest to power beauty with cutting-edge science, Orveda has created OmniPotent Concentrate, a new serum that sits at the crossroads of scientific innovation in the areas of microbiome and cellular longevity,” said Orveda CEO Nicolas Vu. “OmniPotent Concentrate has shown very strong clinical results and is expected to further cement Orveda’s leading position at the nexus of innovation, beauty, and wellness.”

Further highlighting the unique relationship between art, science, and sustainability, Orveda also announced a collaboration with the Azzedine Alaïa Foundation to sponsor aspiring fashion designers from across Africa and Asia. Established in 2007 by the iconic designer Azzedine Alaïa, the Azzedine Alaïa Foundation is committed to preserving and celebrating diverse works across the disciplines of art, fashion, and design. Coty’s collaboration with the Foundation will serve to disrupt mainstream, obsolete expressions of beauty on the global stage, and provide a new arena for underrepresented contemporary creatives to explore and unleash their unique perceptions of beauty.

Infiniment Coty Paris

Over nearly 120 years, Coty has evolved to become a leader in the fragrance industry, anchored by deep industry expertise, leading IP, as well as an iconic portfolio of signature fragrance brands. Further building on this position, Coty is pleased to unveil “Infiniment Coty Paris,” its most ambitious and most premium fragrance project to date.

Harnessing over a century of experience and some of the most creative talents in beauty, Infiniment Coty Paris will be to fragrance what Orveda is to skincare: a leading pioneer in the industry. The collection will ultimately include a range of fourteen diverse scents. It is expected to be launched globally in 2024 and is the first fragrance with patents pending for both the formulation and the packaging.

“Infiniment Coty Paris is a creation that marks a natural progression for the company, fusing beauty, science, and art,” said Nabi. “Today’s announcement is a small teaser of all that is to come in the coming months, when we unveil the full extent of this exciting project to consumers across the globe.”

In celebrating wide-ranging forms of modern beauty, Infiniment Coty Paris has partnered with the 1-54 Contemporary African Art Fair to showcase innovative works from artists across Africa. 1-54 is the first and only international art fair dedicated to highlighting contemporary art from Africa and its diaspora. Two of the works selected as part of the collaboration were displayed at the event at Villa Botanica.

About Coty Inc.

Founded in Paris in 1904, Coty is one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care. Coty serves consumers around the world, selling prestige and mass market products in more than 130 countries and territories. Coty and our brands empower people to express themselves freely, creating their own visions of beauty; and we are committed to making a positive impact on the planet. Learn more at coty.com or on LinkedIn and Instagram.

Aurélie Petit +336 01 33 05 53

[email protected]

KEYWORDS: France Europe

INDUSTRY KEYWORDS: Luxury Other Retail Entertainment Specialty Events/Concerts Celebrity Film & Motion Pictures Cosmetics Retail

MEDIA:

Logo
Logo
Posted on

Lowey Dannenberg P.C. Investigates Bowlero Corp. for Potential Violations of Securities Laws

NEW YORK, May 13, 2023 (GLOBE NEWSWIRE) — Lowey Dannenberg, P.C. a preeminent law firm in obtaining redress for investors, is investigating violations of securities laws and/or other business practices involving the directors and officers of Bowlero Corp. (“Bowlero” or the “Company”) (NYSE: BOWL).

If you are a purchaser of Bowlero common stock and wish to participate, learn more, or discuss the issues surrounding the investigation, please contact our attorneys at (914) 733-7256 or via email to Andrea Farah ([email protected]) or Radhika Gupta ([email protected]) to know more about this investigation.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.

Contact:

Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7256
Email: [email protected]

SOURCE: Lowey Dannenberg



Posted on

In Accordance with NYSE Rule 303A.08, this Press Release Makes Public the Grant of an Employment Inducement Award to Weave Communications’ New Chief Strategy & Services Officer

In Accordance with NYSE Rule 303A.08, this Press Release Makes Public the Grant of an Employment Inducement Award to Weave Communications’ New Chief Strategy & Services Officer

LEHI, Utah–(BUSINESS WIRE)–
As required by the rules of the New York Stock Exchange, Weave Communications, Inc. (NYSE: WEAV), a leading all-in-one customer communications and engagement software platform for small and medium-sized businesses, today announced that it has granted to Marcus Bertilson, Weave’s recently appointed Chief Strategy & Services Officer, on May 10, 2023, the following equity award as an inducement for him to accept employment: restricted stock units relating to 250,000 shares of Weave’s common stock, which vest over three years, with 33% vesting on June 15, 2024 and the remaining 67% over the following 2 years in equal quarterly installments, in each case subject to Mr. Bertilson’s continued service through each vesting date.

The employment inducement award was granted under Weave’s 2022 Inducement Equity Incentive Plan and related form of restricted stock unit agreement. The Compensation Committee of Weave’s Board of Directors approved this award in reliance on the employment inducement exception to shareholder approval provided under Section 303A.08 of the NYSE Listed Company Manual. To comply with the terms of this exemption, the employment inducement award requires prompt public announcement of the award and written notice to the NYSE.

About Weave

Weave is a leading all-in-one customer communication and engagement platform for small- and medium-sized businesses. From the first phone call to the final invoice and every touchpoint in between, Weave connects the entire customer journey. Weave’s software solutions transform how local businesses attract, communicate with and engage customers to grow their business. Weave has set the bar for Utah startup achievement & work culture. In the past year, Weave has been named a G2 leader in Patient Engagement, Optometry, Dental Practice Management and Patient Relationship Management software. To learn more, visit getweave.com/newsroom/.

Investor Relations

Mark McReynolds

Head of Investor Relations

[email protected]

KEYWORDS: Utah United States North America

INDUSTRY KEYWORDS: Professional Services Small Business Technology Start-Up Telecommunications Software Networks

MEDIA:

Logo
Logo
Posted on

Ero Copper Files Technical Report for the Xavantina Operations

VANCOUVER, British Columbia, May 12, 2023 (GLOBE NEWSWIRE) — Ero Copper Corp. (TSX: ERO, NYSE: ERO) (“Ero” or the “Company”) is pleased to announce the filing of its Technical Report for the Xavantina Operations related to the increase in mineral reserves and mineral resources and extension of mine life as previously announced on March 28, 2023.

The Technical Report was prepared in accordance with the Canadian Securities Administrator’s National Instrument 43-101 – Standards of Disclosure for Mineral Projects, and can be found on the Company’s website (www.erocopper.com) and on SEDAR (www.sedar.com). A copy of the Technical Report will also be filed on EDGAR (www.sec.gov).

ABOUT ERO COPPER CORP

Ero is a high-margin, high-growth, clean copper producer with operations in Brazil and corporate headquarters in Vancouver, B.C. The Company’s primary asset is a 99.6% interest in the Brazilian copper mining company, Mineração Caraíba S.A. (“MCSA”), 100% owner of the Company’s Caraíba Operations (formerly known as the MCSA Mining Complex), which are located in the Curaçá Valley, Bahia State, Brazil and include the Pilar and Vermelhos underground mines and the Surubim open pit mine, and the Tucumã Project (formerly known as Boa Esperança), an IOCG-type copper project located in Pará, Brazil. The Company also owns 97.6% of NX Gold S.A. (“NX Gold”) which owns the Xavantina Operations (formerly known as the NX Gold Mine), comprised of an operating gold and silver mine located in Mato Grosso, Brazil. Additional information on the Company and its operations, including technical reports on the Caraíba Operations, Xavantina Operations and Tucumã Project, can be found on the Company’s website (www.erocopper.com), on SEDAR (www.sedar.com), and on EDGAR (www.sec.gov). The Company’s shares are publicly traded on the Toronto Stock Exchange and the New York Stock Exchange under the symbol “ERO”.

FOR MORE INFORMATION, PLEASE CONTACT

Courtney Lynn, VP, Corporate Development & Investor Relations
(604) 335-7504
[email protected]

CAUTION REGARDING FORWARD LOOKING INFORMATION AND STATEMENTS

This press release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation (collectively, “forward-looking statements”). Forward-looking statements include statements that use forward-looking terminology such as “may”, “could”, “would”, “will”, “should”, “intend”, “target”, “plan”, “expect”, “budget”, “estimate”, “forecast”, “schedule”, “anticipate”, “believe”, “continue”, “potential”, “view” or the negative or grammatical variation thereof or other variations thereof or comparable terminology. Forward-looking statements may include, but are not limited to, statements with respect to the future filing of the Technical Report.

Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors that could cause actual results, actions, events, conditions, performance or achievements to materially differ from those expressed or implied by the forward-looking statements, including, without limitation, risks discussed in this press release and in the Company’s Annual Information Form for the year ended December 31, 2022 and dated March 7, 2023 (the “AIF”) under the heading “Risk Factors”.

Forward-looking statements are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements involves statements about the future and are inherently uncertain, and the Company’s actual results, achievements or other future events or conditions may differ materially from those reflected in the forward-looking statements due to a variety of risks, uncertainties and other factors, including, without limitation, those referred to herein and in the AIF under the heading “Risk Factors”.

The Company’s forward-looking statements are based on the assumptions, beliefs, expectations and opinions of management on the date the statements are made, many of which may be difficult to predict and beyond the Company’s control.

Forward-looking statements contained herein are made as of the date of this press release and the Company disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or results or otherwise, except as and to the extent required by applicable securities laws.



Posted on

Catalent Announces Postponement of Third Quarter 2023 Results and Conference Call

Catalent Announces Postponement of Third Quarter 2023 Results and Conference Call

SOMERSET, N.J.–(BUSINESS WIRE)–
Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that in light of the circumstances described in the Company’s Form 12b-25 filed on May 11, 2023, with the Securities and Exchange Commission, and the Company’s ongoing focus on finalizing its financial statements and other disclosures in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the “Form 10-Q”) and completing its quarterly closing processes and procedures, it will be postponing the release of its financial results for the third quarter of fiscal year 2023, ended March 31, 2023, and the conference call previously scheduled for Monday, May 15, 2023 at 8:15 a.m. ET, until Friday, May 19, 2023 at 8:15 a.m. ET.

Third Quarter Fiscal Year 2023 Earnings Conference Webcast

The Company now expects to release financial results for the third quarter of fiscal year 2023, ended March 31, 2023, before the market open on Friday, May 19, 2023, and will host a webcast to discuss the results at 8:15 a.m. ET on the same day. Catalent invites all interested parties to listen to the webcast and view a supplemental slide presentation, both of which will be accessible through Catalent’s website at https://investor.catalent.com. The webcast replay, along with the supplemental slides, will be available for 90 days at https://investor.catalent.com.

About Catalent

Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information www.catalent.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding management’s ongoing review of its third fiscal quarter financial statements and the release of the Company’s fiscal third quarter results. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual future events, results or achievements to be materially different from the Company’s expectations and projections expressed or implied by the forward-looking statements. The important factors include, but are not limited to, the finalization of the Company’s third quarter financial statements, completion of the Company’s quarterly closing processes and procedures, as well as the general business, financial and accounting risks and the other important factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended June 30, 2022, filed with the U.S. Securities and Exchange Commission, or the SEC, and the Company’s other filings with the SEC. Forward-looking statements speak only as of the date of this press release and are based on information available to the Company as of the date of this press release, and the Company assumes no obligation to update such forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Paul Surdez, Catalent, Inc.

(732) 537-6325

[email protected]

Media Contact:

Chris Halling

+44 (0)7580 041073

[email protected]

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Science Other Science Biotechnology Research Pharmaceutical General Health Health Other Health

MEDIA:

Posted on

Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy

Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy

– Advisory committee voted 8-6 in support of accelerated approval of SRP-9001

– Regulatory action date is May 29, 2023

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in support of accelerated approval of SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulatory patients with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene.

“Today’s advisory committee outcome is extremely important to the patient community, who are in urgent need of new therapies,” said Doug Ingram, president and chief executive officer, Sarepta. “With the May 29 action date our top priority, we will work collaboratively with the FDA to complete the review of our BLA for SRP 9001. We extend our sincere appreciation to the families, clinicians, FDA presenters and committee members who participated in today’s panel and to all those who provided input and comments both in the written record and in the open public hearing.”

SRP-9001 is intended to treat the underlying cause of Duchenne, which is characterized by mutations in the dystrophin gene that results in the lack of dystrophin protein. In the absence of dystrophin, which is required to strengthen and protect muscles, muscles become weakened and damaged. SRP-9001 is intended to deliver a gene that codes for a shortened, functional form of dystrophinto muscle cells. The committee’s positive vote is based on the evaluation of the totality of evidence including the SRP-9001 product design as well as biological and empirical data. SRP-9001 is supported by non-clinical evidence in addition to efficacy and safety data from studies 101, 102 and 103 as well as an integrated analysis across these three clinical studies comparing functional results to a propensity-score-weighted external control (EC).

The CTGTAC’s vote, while not binding, will be considered by the FDA when making its decision regarding the potential accelerated approval of SRP-9001. The Biologics License Application (BLA) for SRP-9001 is currently under priority review by the FDA with a regulatory action date of May 29, 2023.

About SRP-9001 (delandistrogene moxeparvovec)

SRP-9001 (delandistrogene moxeparvovec) is an investigational gene transfer therapy designed to address the underlying cause of DMD through the targeted production of functional components of dystrophin in muscle tissue. Sarepta is responsible for global development and manufacturing for SRP-9001 and plans to commercialize SRP-9001 in the United States upon receiving FDA approval. In December 2019, Roche partnered with Sarepta to combine Roche’s global reach, commercial presence and regulatory expertise with Sarepta’s gene therapy candidate for Duchenne to accelerate access to SRP-9001 for patients outside the United States.

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a rare, fatal neuromuscular genetic disease that occurs in approximately one in every 3,500-5,000 newborn males worldwide. DMD is caused by a change or mutation in the gene that encodes instructions for dystrophin. Symptoms of DMD usually appear in infants and toddlers. Affected children may experience developmental delays such as difficulty in walking, climbing stairs or standing from a sitting position. As the disease progresses, muscle weakness in the lower limbs spreads to the arms and other areas. Most patients require full-time use of a wheelchair in their early teens, and then progressively lose the ability to independently perform activities of daily living such as using the restroom, bathing and feeding. Eventually, increasing difficulty in breathing due to respiratory muscle dysfunction requires ventilation support, and cardiac dysfunction can lead to heart failure. The condition is universally fatal, and patients usually succumb to the disease in their twenties.

About Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information

We routinely post information that may be important to investors in the ‘For Investors’ section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Forward-Looking Statements

This press release contains “forward-looking statements.” Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, business plans, priorities, research and development programs;SRP-9001’s potential for accelerated approval; the Company’s plans to continue working with the FDA as they complete their review of the SRP-9001 BLA; the potentially transformative benefits of SRP-9001; and that the FDA is not bound by the advisory committee recommendation but takes its advice in consideration when reviewing applications.

Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: the FDA may not approve the BLA for SRP-9001 by the application PDUFA date or at all; we may not be able to comply with all FDA requests, including with respect to our SRP-9001 BLA, in a timely manner or at all; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business, as well as the development of our product candidates and our financial and contractual obligations; our dependence on certain manufacturers to produce our products and product candidates, including any inability on our part to accurately anticipate product demand and timely secure manufacturing capacity to meet product demand, may impair the availability of product to successfully support various programs; our data for SRP-9001 may not be sufficient for obtaining regulatory approval; success in preclinical and clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or with advisory committee recommendations, or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; the commencement and completion of our clinical trials and announcement of results may be delayed or prevented for a number of reasons, including, among others, denial by the regulatory agencies of permission to proceed with our clinical trials, or placement of a clinical trial on hold, challenges in identifying, recruiting, enrolling and retaining patients to participate in clinical trials and inadequate quantity or quality of supplies of a product candidate or other materials necessary to conduct clinical trials; different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results, and even if we believe the data collected from clinical trials of our product candidates are positive, these data may not be sufficient to support approval by the FDA or other global regulatory authorities; we may not be able to execute on our business plans, including meeting our expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing our product candidates to market, for various reasons, many of which may be outside of our control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates, and the ongoing COVID-19 pandemic; and those risks identified under the heading “Risk Factors” in our most recent Annual Report on Form 10-K for the year ended December 31, 2022 and Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company’s business, results of operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law.

Investor Contact:

Ian Estepan, 617-274-4052

[email protected]

Media Contact:

Tracy Sorrentino, 617-301-8566

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: FDA Health Research Pharmaceutical Science Biotechnology

MEDIA:

Logo
Logo